Search PubMed⌕ Search

Biomedical subjects

G Pescetti

Publications and source records attributed to G Pescetti.

At least 19 recordsLinked to original sources
PubMed1989

Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.

Lonidamine (LND) interferes with the energy mechanisms of neoplastic cells and decreases the oxygen consumption in human and experimental tumors. The present study was performed in advanced non-small cell lung cancer patients, previously untreated, to confirm the preliminary data of activity against this kind of tumor. LND was given orally in three divided doses increasing to 250 mg/m2 over 4 days. Thirty-six patients were evaluable for toxicity and 33 for response. Partial responses were 3 (9%) and stabilization of disease 15 (45,5%). Recorded side effects (testicular pain, nausea and vomiting, skin hyperesthesia) were mostly mild to moderate with the exclusion of myalgias. Chronic treatment was devoid of haematological, renal, cardiac and pulmonary toxicities. LND as single agent seems to be marginally active in advanced non-small cell lung cancer.

Aged↗
PubMed1986

Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.

Twenty-nine patients with advanced non small cell lung cancer (NSCLC) were treated with a combination of high-dose cisplatin and divided-dose vinblastine. In 27 evaluable patients 15% reached partial response and 59% stable disease. Extension of disease, histological type, performance status and weight loss had no relationship to response. Median duration of response was 10.2 months with a median survival time of 15.4 months in responding patients compared with 14 months of stable disease (p:n.s.) and 4.8 months of progressive disease (p less than 0.001). Gastrointestinal, neurological side effects and the development of a severe debilitation syndrome were the most troublesome toxicities of this treatment. The regimen is not generally suitable for treatment of advanced NSCLC.

Adult↗
PubMed1985

Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.

69 patients with unresectable non-small cell lung cancer, previously untreated, received cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 4, 6, 8 at 4-week intervals. 66 patients were evaluable for tumor response and toxicity. Overall objective response was 25.7% (3 complete responses and 14 partial responses). Response rate in limited disease was 41% and in patients with performance score 0 it was 40%. Squamous cell carcinoma and adenocarcinoma responded in 31 and 24% of evaluable patients. Complete response was associated with a long duration of remission. Median survival time of responding patients was significantly superior to the median of nonresponding patients (p less than 0.001) but compared to stable disease no statistical significance was demonstrable (p greater than 0.05). Hematological and renal toxicity of proposed regimen was generally mild. Nausea and vomiting were the most noxious side effects.

Aged↗
PubMed1984

[Diagnosis of tuberculosis today].

Authors analyse the main aspects about the diagnosis of tuberculosis and they emphasize that the bacteriological and immunological tests are very important, beside the clinical, radiologic and hematic picture. As regards bacteriological research, Authors dwell upon the significance of repeated sputum specimens and they reevaluate the use of fluorochrome staining. The immunological "in vivo" tests are represented by tuberculin skin test, that must be correctly made and valued to avoid wrong unresponsiveness, at the other hand also caused by host factors. About immunological "in vitro" tests, Authors report the good prospects opened by the serological diagnosis with an immunoenzymatic method specific for S antigen of M. tuberculosis.

Antigens, Bacterial↗
PubMed1984

Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.

Twenty patients with unresectable non-small cell lung cancer (10 squamous cell carcinoma, 7 adenocarcinoma, 3 large cell carcinoma), previously untreated, received etoposide 300 mg/m2 by oral route days 1-3-5 every three weeks. No complete or partial remissions were observed but only two minor responses. There were 7 stable diseases and 11 progressive diseases. Myelosuppression activity was usually mild and gastro-intestinal side effects were the most prominent. In this trial etoposide by oral route has shown only marginal activity against non-small cell lung cancer.

Administration, Oral↗
PubMed1980

[Clinical aspects of viral respiratory infections].

The Authors deal with some clinical aspect of the commonest types of respiratory tract viral infections. After a description of the characteristics of the most important diseases (common cold, ARD, influenza, viral pneumonia) they deal with some particular problem difficult in resolution, both from a pathogenetic and clinical viewpoint and quite constant bacterial over infection, the cardiac complications, th possible evolution to fibrosis and the relationship between viral infections and asthma. The nowadays problem of immunological and chemotherapeutic prevention of viral infections, particularly of type A influenza, is also discussed.

Adenoviridae Infections↗
PubMed1980

[Ultrastructure of the pulmonary alveolus. Correlations with the endoalveolar tensioactive system].

The knowledge of chemical structure and physiologic role of endoalveolar tensioactive system are a progress of the last ten years. The authors deal with the origin, fate and relationships with pulmonary surfactant metabolism of alveolar cells. Morphology and functions of alveolar-capillary membrane, type I and II cells, bronchiolar non-ciliated Clara cells and alveolar macrophages have been outlined. Lamellar bodies, alveolar type II cells intracitoplasmatic inclusions were particularly considered, as well as tubular myeline structures.

Epithelium↗
PubMed1980

[Sarcoidosis].

Explore the source record for details and available documents.

Adrenal Cortex Hormones↗
PubMed1979

Radioisotopic labelling of endoalveolar surface-active phospholipidic fractions from rabbit pulmonary lavage.

A simple method of detecting endoalveolar tensioactive system fractions employing intravenously injected 131I-triolein has been devised. The tracer has been administered to 7 adult rabbit groups then sacrificed at different time intervals after the injection. Endoalveolar tensioactive system lipidic fractions collected by pulmonary lavage have been separated with thin-layer chromatography and their radioactivity evaluated by scanning plates. Endoalveolar tensioactive system fractions containing considerable amounts of C 18 fatty acids have been selectively labelled.

Animals↗
PubMed1977

[Physiopathology and clinical aspects of the alveolar surface active system (pulmonary surfactant)].

Existing knowledge of the pulmonary alveolar surfactant system is summarised in monographic form. Particular attention is directed to its physiopathology, synthesis mechanisms, and pathology in man, as well as to the methods used into its clinical investigation. Stress is laid on the importance of the system in the direct or indirect determination of many cardiac and pneumocardiac diseases. Ways in chich deficiencies on the part of this system can be treated are critically discussed.

Adult↗